The rewarding effects of alcohol after bariatric surgery: do they change and are they associated with pharmacokinetic changes?
Bariatric surgery
Pharmacokinetics
Reinforcement
Reward
Weight loss surgery
Journal
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
ISSN: 1878-7533
Titre abrégé: Surg Obes Relat Dis
Pays: United States
ID NLM: 101233161
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
07
05
2021
revised:
23
07
2021
accepted:
16
08
2021
pubmed:
30
9
2021
medline:
29
3
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Research shows that surgery patients who have undergone Roux-en-Y gastric bypass (RYGB) are at increased risk for an alcohol use disorder (AUD). However, the mechanisms through which this increased risk is incurred are poorly understood. A host of variables have been proposed as potentially causal in developing AUDs, but empirical examination of many of these variables in human samples is lacking. Our objective was to examine the extent to which alcohol pharmacokinetics (PK), the rewarding effects of alcohol, and the relationship between these variables change from before to after weight loss surgery. Large healthcare facility in the Midwest United States METHODS: Thirty-four participants completed assessments before and 1 year after RYGB. They completed laboratory sessions and provided data on the PK of alcohol and the extent to which alcohol was reinforcing to them at each timepoint. Findings show that the PK effects of alcohol (P < .01) and how rewarding alcohol was reported to be (P < .01) changed from before to 1 year after weight loss surgery. Further, statistically significant increases in the association between these variables were witnessed from before to 1 year after surgery (P < .01). These results implicate changes (from before surgery to one year after) in the reinforcing and PK effects of alcohol as possible mechanisms for increased risk of alcohol use disorder following Roux-en-Y gastric bypass surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Research shows that surgery patients who have undergone Roux-en-Y gastric bypass (RYGB) are at increased risk for an alcohol use disorder (AUD). However, the mechanisms through which this increased risk is incurred are poorly understood. A host of variables have been proposed as potentially causal in developing AUDs, but empirical examination of many of these variables in human samples is lacking.
OBJECTIVES
OBJECTIVE
Our objective was to examine the extent to which alcohol pharmacokinetics (PK), the rewarding effects of alcohol, and the relationship between these variables change from before to after weight loss surgery.
SETTING
METHODS
Large healthcare facility in the Midwest United States METHODS: Thirty-four participants completed assessments before and 1 year after RYGB. They completed laboratory sessions and provided data on the PK of alcohol and the extent to which alcohol was reinforcing to them at each timepoint.
RESULTS
RESULTS
Findings show that the PK effects of alcohol (P < .01) and how rewarding alcohol was reported to be (P < .01) changed from before to 1 year after weight loss surgery. Further, statistically significant increases in the association between these variables were witnessed from before to 1 year after surgery (P < .01).
CONCLUSION
CONCLUSIONS
These results implicate changes (from before surgery to one year after) in the reinforcing and PK effects of alcohol as possible mechanisms for increased risk of alcohol use disorder following Roux-en-Y gastric bypass surgery.
Identifiants
pubmed: 34583891
pii: S1550-7289(21)00410-X
doi: 10.1016/j.soard.2021.08.011
pmc: PMC8792168
mid: NIHMS1738025
pii:
doi:
Substances chimiques
Ethanol
3K9958V90M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190-195Subventions
Organisme : NIGMS NIH HHS
ID : P30 GM114748
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA022336
Pays : United States
Informations de copyright
Copyright © 2022 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
Références
Addiction. 2003 Mar;98(3):291-303
pubmed: 12603229
JAMA Surg. 2013 Apr;148(4):374-7
pubmed: 23716012
J Clin Invest. 2020 Aug 3;130(8):4370-4381
pubmed: 32427584
Biochem Pharmacol. 2019 Jun;164:106-114
pubmed: 30954487
Curr Pharm Des. 2018 Feb 12;23(39):6050-6061
pubmed: 28831923
Ann Transl Med. 2018 Apr;6(8):148
pubmed: 29862237
Surg Obes Relat Dis. 2019 Jul;15(7):1160-1169
pubmed: 31182414
Curr Psychiatry Rep. 2019 Aug 13;21(9):85
pubmed: 31410716
Neuropharmacology. 2009;56 Suppl 1:3-8
pubmed: 18617195
Br J Clin Pharmacol. 2002 Dec;54(6):587-91
pubmed: 12492605
Adv Nutr. 2015 Jan 15;6(1):96-101
pubmed: 25593148
Obes Surg. 2001 Aug;11(4):464-8
pubmed: 11501356
Obes Surg. 2013 Jul;23(7):920-30
pubmed: 23440511
Synapse. 2018 Jul 10;:
pubmed: 29992624
Eur Neuropsychopharmacol. 2016 Jul;26(7):1190-200
pubmed: 27184782
Obesity (Silver Spring). 2013 Dec;21(12):2444-51
pubmed: 23520203
JAMA. 2012 Jun 20;307(23):2516-25
pubmed: 22710289
Behav Pharmacol. 1993 Feb;4(1):29-36
pubmed: 11224168
Front Psychol. 2014 Sep 17;5:919
pubmed: 25278909
Surg Obes Relat Dis. 2018 Mar;14(3):277-283
pubmed: 29305304
JAMA Surg. 2015 Nov;150(11):1096-8
pubmed: 26244751
Surg Obes Relat Dis. 2017 Aug;13(8):1392-1402
pubmed: 28528115